Kaleido Biosciences, Inc. (KLDO) stock soared 75.29% in the pre-market trading session at the price of $0.30 despite no fundamental updates.
KLDO Filed Form 8-K
On 8th April 2021, KLDO delivered legal notice to Nasdaq about its intentions to willingly delist its common stock, valued at US$0.001 per share, from the Nasdaq Stock Market in compliance with the stock’s termination of all operations. The company hopes to file a Form 25 with SEC on 18th April 2022 to make the delisting of the common stock effective under Section 12(b) of the Exchange Act. The delisting will officially become effective on 28th April 2022, ten days following the filing of Form 25. After the delisting, KLDO plans to file a Form 15 with the U.S. SEC to discontinue its obligations of Exchange Act reporting.
KLDO Market Updates
KLDO stock has made captivating improvements till now in recognizing potential MMTs with preferred effects on the infant microbiome population. The stock’s keen research in the microbiome combined with its proprietary platform had positioned it to advance. The expansion of this partnership will enhance the stock’s expertise in glycans modulation to support an infant’s immunity.
Additionally, the management keeps working closely with their allies at the COPD Foundation. The company remains on a trail to start a Phase-II clinical trial of KB109 in COPD by Q1 of 2022. Meanwhile, KLDO has already planned to initiate trials in its two indications by this year. Looking onwards, KLDO will present the immuno-modulatory outcomes of its novel microbiome metabolic therapies.
Kaleido is a clinical-stage biotechnology corporation that leverages a differentiated, proprietary, and small-molecule technology to treat inflammatory conditions and disorders. This approach targets the local microbiome to resurrect gut-immune homeostasis in infants. The stock has created a proprietary product portfolio to facilitate the cost-efficient and quick discovery and expansion of microbiome metabolic therapies.